Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use?

Our data confirm that BEL is effective in controlling disease activity, and in recent years BEL has been considered as an earlier treatment option before other IS. Early introduction of BEL can be at least as effective as a step-up approach and can help to reduce the GC dosage.